drugset / Trial / NCT04991025
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to explore adding the study drug certolizumab to standard chemotherapy as it may reduce the inflammation caused by the cancer and make the chemotherapy more effective in shrinking the cancer. This study will examine whether adding certolizumab to the usual treatment approach is better than, the same as, or worse than the usual approach alone.
Timeline
- Start
- 2022-10-19
- Primary completion
- 2026-10
- Completion
- 2026-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Certolizumab | Protein / enzyme biologic | 400 mg | Subcutaneous |
| Background | Carboplatin | Small molecule | 5 unknown | — |
| Background | Cisplatin | Other / unclassified | 75 mg/m2 | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Nivolumab | Monoclonal antibody | 360 mg | Intravenous |
| Background | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |